Results 81 to 90 of about 5,184 (154)

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

JAMA Netw Open
Png ME, Harris V, Yu LM, Little P, Hobbs FDR, Butler CC, Petrou S, PANORAMIC Trial Collaborative Group.   +7 more
europepmc   +1 more source

Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. [PDF]

Front Cell Infect Microbiol
Zhang Y, Yang X, Sun L, Zhang R, Fan W, Lin N, Lin B.   +6 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID diabetes risk among an older adult cohort: a target trial emulation study. [PDF]

BMC Med
Guo Z, Wei Y, Yang A, Wong CKH, Xiong X, Wang K, Lin G, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Zhao S, Mok CKP, Hui DSC, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

Pharmacist follow-up of patients prescribed nirmatrelvir/ritonavir: a single-center retrospective analysis. [PDF]

J Pharm Health Care Sci
Shigeno A, Ohashi Y, Masui R, Kiryu A, Nagashima K, Ohashi H, Seto K, Masuda J, Teruya K, Ujiie M, Ohmagari N, Nishimura T.   +11 more
europepmc   +1 more source

Association of Nirmatrelvir-ritonavir with intubation or mortality risks in severe COVID-19 patients: a comparative study. [PDF]

BMC Infect Dis
Luo W, Li KY, Zhu W, Dai C, Lin J, Lu F, Chen Q, Wang W, Zhuang Q, Lin Y.   +9 more
europepmc   +1 more source

Viral kinetics in adults with Covid-19 treated with nirmatrelvir-ritonavir or molnupiravir: a population-based, observational cohort study. [PDF]

Virol J
Prager M, Ensle D, Eser H, Glötzl F, Riedl B, Szell M, Valipour A, Zoufaly A, Wenisch C, Haider D, Burgmann H, Thalhammer F, Götzinger F, Jilma B, Karnthaler U, Zeitlinger M, Jorda A.   +16 more
europepmc   +1 more source

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. [PDF]

Clin Infect Dis
Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, Boyle A, Senneker T, George J, Lund C, Belperio P, Crew P, Eschenauer G, Scarsi KK, Khoo SH, Pau A, Marzolini C, LiON-PK collaboration .   +17 more
europepmc   +1 more source

Effectiveness of Antivirals Nirmatrelvir-Ritonavir and Molnupiravir in Viral Sepsis: Retrospective Cohort Study. [PDF]

JMIR Public Health Surveill
Lee TTL, Lyu AC, Jiang TT, Chan SCL, Chan CY, Yip ETF, Luk LYF, Ho JWK, So KWL, Tsui OWK, Lam ML, Lee SY, Yamamoto T, Tong CK, Wong MS, Wong ELY, Wai AKC, Rainer TH.   +17 more
europepmc   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada. [PDF]

Pharmacoepidemiol Drug Saf
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, Leal J, Rennert-May E, Rafferty E, Williamson T, Klarenbach SW.   +10 more
europepmc   +1 more source

Underutilization of nirmatrelvir/ritonavir in eligible COVID-19 patients. [PDF]

Eur J Clin Microbiol Infect Dis
de Arpe CF, Homen R, Valls-Carbó A, Barrado J, Olmos-Mata C, Pérez-Somarriba J, Muñoz-Gomez A, Núñez-Orantos MJ, Cabello-Clotet N, Estrada V.   +9 more
europepmc   +1 more source